RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Corruption Risk: Responding to Critical Issues in the Pharmaceutical Industry

Corruption Risk: Responding to Critical Issues in the Pharmaceutical Industry

Posted 01 November 2010

As regulators and law enforcement officials in the US and abroad shine brighter spotlights on the pharmaceutical industry, it is more important than ever for life sciences companies to have programs to evaluate, mitigate and monitor corruption risk. A robust anti-corruption compliance program provides a critical "rule book" for life sciences companies conducting business in today's global economy.

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe